Benchmark indices have performed well in election years going by four decades of history and despite spikes in volatility, the median returns in election years have been 17%. As per ICICI Direct, the outperformance of PSU banks will only amplify and investors should also raise their exposure to IT stocks ignoring the noise.
Thus, projecting a target of 21,000 by December 2023 as it is price parity of the June-December 2022 rally (15,183-18,887) projected from March 2023 low of 16,828. "The seasonality pattern gels well with our price structure model and classical chart pattern projection of 20,700-21,000 in CY23. Meanwhile, strong support is placed at 18,700," the report said.
Gufic Bio Share Price: Find the latest news on Gufic Bio Stock Price. Get all the information on Gufic Bio with historic price charts for NSE / BSE. Experts & Broker view also get the Gufic Bio Ltd. buy/sell tips detailed news, announcements, Forecasts, Analysts, Valuation, Earning forecasts, Estimates, Recommendations, Analysts Ratings, financial report, company information, annual report, balance sheet, profit & loss account, results and more.
Black Fungus: 5 pharma cos get DCGI s nod to produce Amphotericin B
The five companies that got DCGI s nod to manufacture Amphotericin B liposomal injection are Alembic Pharmaceuticals, Emcure Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, and Natco Pharma
BusinessToday.In | May 21, 2021 | Updated 11:06 IST
Amphotericin B is used in the treatment of black fungus or mucormycosis and is currently in short supply
The Drug Controller General of India (DCGI) has granted approval to five pharma companies to start manufacturing antifungal anti-fungal drug Amphotericin B liposomal injection, whose demand has increased in the wake of a surge in black fungus infections.
The five companies that got DCGI s nod are Alembic Pharmaceuticals, Emcure Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, and Natco Pharma. Presently six firms - BDR Pharma, Bharat Serums and Vaccines, Mylan, Sun Pharma, Cipla, and Life Care - are producing the drug.
Stop loss: Rs 138 On the weekly charts, NOCIL started its up move from 45 in March 2020. A continuous, steady rise followed, supported by higher bottoms and the stock made a high of 199 in March 2021. Since July 2020, it has been trading above the averages and the super trend is in the positive mode. Recently, the stock traded in the range of 157 and 185 for a month. A weekly green candle with the range of 173-184 has formed, supported by volumes and the Vortex and KST Indicators are in the positive mode. The stock has the strength to achieve a target of 250-300 in the coming days. The intermediate buy area is (181-174)-167-(159-155) and a Stop Loss of 138 on a closing basis should be observed in this trade.